TUSTIN, Calif. (


) --

Peregrine Pharmaceuticals


disclosed new pancreatic cancer study results Wednesday showing its cancer drug bavituximab behaves very much like a placebo.

In a phase II study of 70 patients with advanced pancreatic cancer, the combination of bavituximab and gemcitabine prolonged survival by just 12 days over gemcitabine alone. Peregrine didn't disclose a p value for the survival analysis, so assume it was large and definitely not statistically significant.

Neither the 5.8 month median overall survival in the bavituximab-gemcitabine arm of Peregrine's phase II study nor 5.2 months in the gemcitabine arm was any better than the historical 5-6 month survival typically seen when pancreatic cancer patients are treated with gemcitabine alone.



(CELG) - Get Report

recent phase III study, which enrolled more than 800 patients, the combination of Abraxane plus gemcitabine

yielded a median overall survival of 8.5 months

compared to 6.7 months for gemcitabine alone.

Overall survival was the

primary endpoint of the bavituximab pancreatic cancer study

, which dulls the clinical meaning of the response rate benefit touting by Peregrine in Wednesday's press release.

Patients treated with bavituximab-gemcitabine had a 28% tumor response rate compared to 13% for patients treated with gemcitabine alone. Peregrine fails to note if the response rate difference was statistically significant, or if response rates were confirmed by independent review.

Peregrine has a habit of releasing unverified response rate data from bavituximab studies, only to see those response rates

nullified by independent review


And of course, Peregrine's credibility was shot when it was forced to rescind last year's bavituximab lung cancer data due to improper study conduct.

In a statement Wednesday, Peregrine said it hoped to find subsets of pancreatic cancer patients where bavituximab may work better. Data mining negative study results is the last bastion of hope for desperate drug developers.

-- Reported by Adam Feuerstein in Boston.

Follow @AdamFeuerstein

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.